These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25536639)

  • 1. Effects on anemia of drug adjustment in patients with chronic hepatitis C during telaprevir-combined therapy.
    Tamori A; Kioka K; Sakaguchi H; Enomoto M; Hai H; Kawamura E; Hagihara A; Fujii H; Uchida-Kobayashi S; Iwai S; Morikawa H; Murakami Y; Kawasaki Y; Tsuruta D; Kawada N
    Ann Hepatol; 2015; 14(1):28-35. PubMed ID: 25536639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1.
    Oze T; Hiramatsu N; Yakushijin T; Yamada R; Harada N; Morishita N; Yamada A; Oshita M; Kaneko A; Suzuki K; Inui Y; Tamura S; Yoshihara H; Imai Y; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hayashi N; Takehara T
    J Gastroenterol; 2015 Mar; 50(3):313-22. PubMed ID: 24806033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of telaprevir, pegylated interferon α-2b and ribavirin triple therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Kawaguchi Y; Iwane S; Kumagai T; Yanagita K; Yasutake T; Ide Y; Otsuka T; Eguchi Y; Ozaki I; Akiyama T; Kawazoe S; Mizuta T
    Intern Med; 2015; 54(20):2551-60. PubMed ID: 26466688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate.
    Morihara D; Watanabe H; Takata K; Iwashita H; Tsuchiya N; Kunimoto H; Kuno S; Fukunaga A; Yotsumoto K; Tanaka T; Sakurai K; Hirano G; Yokoyama K; Nishizawa S; Yoshikane M; Anan A; Takeyama Y; Kitamura Y; Iwata K; Irie M; Shakado S; Sohda T; Sakisaka S
    Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):55-64. PubMed ID: 25370853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.
    Ogawa E; Furusyo N; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Oct; 59(4):667-74. PubMed ID: 23707372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients.
    Ozeki I; Akaike J; Karino Y; Arakawa T; Kuwata Y; Ohmura T; Sato T; Kamiya N; Yamada I; Chayama K; Kumada H; Toyota J
    J Gastroenterol; 2011 Jul; 46(7):929-37. PubMed ID: 21556829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-α2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.
    Kawakami Y; Suzuki F; Karino Y; Toyota J; Kumada H; Chayama K
    Antivir Ther; 2014; 19(3):277-85. PubMed ID: 24192751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C.
    Flisiak R; Shiffman M; Arenas J; Cheinquer H; Nikitin I; Dong Y; Rana K; Srinivasan S
    PLoS One; 2016; 11(10):e0164563. PubMed ID: 27749900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1.
    Oze T; Hiramatsu N; Yakushijin T; Yamada R; Harada N; Morishita N; Oshita M; Mita E; Ito T; Inui Y; Inada M; Tamura S; Yoshihara H; Imai Y; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hayashi N; Takehara T
    J Viral Hepat; 2015 Mar; 22(3):254-62. PubMed ID: 25081140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
    Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
    N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telaprevir for previously untreated chronic hepatitis C virus infection.
    Jacobson IM; McHutchison JG; Dusheiko G; Di Bisceglie AM; Reddy KR; Bzowej NH; Marcellin P; Muir AJ; Ferenci P; Flisiak R; George J; Rizzetto M; Shouval D; Sola R; Terg RA; Yoshida EM; Adda N; Bengtsson L; Sankoh AJ; Kieffer TL; George S; Kauffman RS; Zeuzem S;
    N Engl J Med; 2011 Jun; 364(25):2405-16. PubMed ID: 21696307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telaprevir for retreatment of HCV infection.
    Zeuzem S; Andreone P; Pol S; Lawitz E; Diago M; Roberts S; Focaccia R; Younossi Z; Foster GR; Horban A; Ferenci P; Nevens F; Müllhaupt B; Pockros P; Terg R; Shouval D; van Hoek B; Weiland O; Van Heeswijk R; De Meyer S; Luo D; Boogaerts G; Polo R; Picchio G; Beumont M;
    N Engl J Med; 2011 Jun; 364(25):2417-28. PubMed ID: 21696308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
    Buti M; Agarwal K; Horsmans Y; Sievert W; Janczewska E; Zeuzem S; Nyberg L; Brown RS; Hézode C; Rizzetto M; Paraná R; De Meyer S; De Masi R; Luo D; Bertelsen K; Witek J
    Gastroenterology; 2014 Mar; 146(3):744-753.e3. PubMed ID: 24316262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
    Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
    Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.
    Inoue T; Hmwe SS; Shimada N; Kato K; Ide T; Torimura T; Kumada T; Toyoda H; Tsubota A; Takaguchi K; Wakita T; Tanaka Y
    PLoS One; 2017; 12(1):e0170667. PubMed ID: 28118381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study.
    Ogawa E; Furusyo N; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1076-85. PubMed ID: 24099469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
    McHutchison JG; Everson GT; Gordon SC; Jacobson IM; Sulkowski M; Kauffman R; McNair L; Alam J; Muir AJ;
    N Engl J Med; 2009 Apr; 360(18):1827-38. PubMed ID: 19403902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.
    Liu CH; Liu CJ; Huang CF; Lin JW; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Lee CY; Chen SI; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
    Gut; 2015 Feb; 64(2):303-11. PubMed ID: 24747867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b.
    Flisiak R; Kawazoe S; Znoyko O; Assy N; Gadano A; Kao JH; Lee KS; Zwirtes R; Portsmouth S; Dong Y; Xu D; Kumada H; Srinivasan S
    J Interferon Cytokine Res; 2016 Nov; 36(11):635-643. PubMed ID: 27327078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.